Refine by
In Vitro Cell Articles & Analysis
40 news found
About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. ...
About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
Due to these advantages, NIR quantum dots have great potential in early cancer diagnosis, tumor imaging in vivo, and high-resolution electron microscopy of cancer cells. In recent years, the development of various modification methods has expanded the potential applications of NIR quantum dots in biomedical applications. ...
In hematologic malignancies, preclinical studies showed that IO-202 converts a “don’t kill me” to a “kill me” signal by activating T cell killing and converts a “don’t find me” to a “find me” signal by inhibiting infiltration of blood cancer cells. In the context of solid tumors, preclinical data ...
AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo. ...
Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclib’s inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib. ...
Batch manufacturing begins at the fermentation or cell culturing stage. Subsequently, therapeutic enzymes are expressed in a cell culture bioreactor to robust the reproducible protein purification or downstream processing (DSP) of the target product. ...
About Hemostemix Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and ...
New in vitro CAR-NK cell iCAR screening data demonstrate that Senti Bio has tested more than 20 different NOT GATE architectures to identify the most robust intracellular functional domain for the SENTI-202 NOT GATE circuit. In vitro data demonstrate significant NOT GATE-mediated protection of primary healthy hematopoietic stem ...
About Hemostemix Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and ...
“We believe by targeting the LILRB4 checkpoint, IO-202 may reverse the immunosuppressive effects of tumor associated monocytic myeloid cells, enhance dendritic cell function, and promote T cell activation – thereby, unleashing the antitumor activities of the immune system and increasing the therapeutic benefit of T ...
Oral presentation highlights: Utilizing Araris' linker technology, an anti-Nectin-4 ADC was generated within 24 hours resulting in highly homogenous and pure ADCs with a DAR of ~ 2 and > 98% monomeric content. In In-vitro assays against target positive cell lines, the Araris ADC demonstrated low nM-range cytotoxicity similar to approved enfortrumab-vedotin ...
Oral presentation highlights: Utilizing Araris’ linker technology, an anti-Nectin-4 ADC was generated within 24 hours resulting in highly homogenous and pure ADCs with a DAR of ~ 2 and > 98% monomeric content. In In-vitro assays against target positive cell lines, the Araris ADC demonstrated low nM-range cytotoxicity similar to approved ...
About Hemostemix Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and ...
About Hemostemix Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and ...
“We are pleased to partner with Hemostemix and contribute our proprietary AI-based genomic and phenotypic tools, to enhance their ground-breaking personalized stem cell therapeutics. This collaboration exemplifies the power and precision of personalized autologous medicine,” stated Dr. ...